IASO Biotherapeutics
Industry
- Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Antibodies
- Pharmaceuticals
Other Names/Subsidiaries
- Nanjing IASO Biotherapeutics
Latest on IASO Biotherapeutics
China’s cell therapy market will grow into an exclusive space for domestic companies, at least over the coming years, after Gilead Sciences, Inc. on 13 September divested through Kite Pharma, Inc.
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Orum, Vertex Ink Novel Protein-Deg
Chinese immuno-oncology specialist CARsgen Therapeutics and Huadong Medicine Co., Ltd. , its domestic commercialization partner, on 1 March won regulatory approval in China for zevorcabtagene autol
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Novartis To Pay Argo $185m Up Fron